secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001339970-26-000006
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma FY2025 cash $80.9M; Phase 3 sarcoidosis study misses primary endpoint
--------------------------------------------------------------------------------

- Phase 3 EFZO-FIT missed primary endpoint (corticosteroid dose reduction at week 48), but showed benefit in KSQ-Lung (p=0.0479) and other secondary measures.
- Type C FDA meeting scheduled mid-April 2026 to review EFZO-FIT results and determine path forward for efzofitimod in pulmonary sarcoidosis.
- Phase 2 EFZO-CONNECT in SSc-ILD on track to complete enrollment in first half 2026; interim data reported Q2 2025.
- Year-end 2025 cash position $80.9 million; R&D expenses $60.2 million, G&A $17.6 million for the year.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/0001339970-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000006/atyr-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer